Digital Health
Americans Wary of Generative AI in Healthcare: Trust and Transparency Key to Adoption
What You Should Know: – A new survey, Generative AI in Healthcare: Gaining Consumer Trust, from Wolters Kluwer Health reveals significant concerns among…
What You Should Know:
– A new survey, Generative AI in Healthcare: Gaining Consumer Trust, from Wolters Kluwer Health reveals significant concerns among Americans regarding the use of generative AI (GenAI) in healthcare.
– While many see its potential to improve care, the lack of transparency and validation around data sources raises major trust issues.
Lack of Trust & Transparency
Key findings of the report include:
– Lack of transparency: 86% of Americans worry about not knowing the source and validation of medical information used by GenAI.
– Filtering out noise: 82% are concerned about GenAI relying on unfiltered internet searches.
– Half fear false information: 49% worry about GenAI generating inaccurate medical data.
Building Trust through Responsible Implementation
– Established sources: 63% are more comfortable if GenAI content comes from trusted healthcare sources and is regularly updated.
– Medical expert involvement: 86% want medical professionals involved in GenAI content creation.
– Industry reputation: 81% trust companies with a strong track record in healthcare.
– Clear communication: 89% want clinicians to be transparent about GenAI use.
Positive Outlook for GenAI in Healthcare
– 34% expect widespread GenAI adoption within 5 years, 19% in 1-2 years.
– 45% see GenAI improving healthcare through accurate medical image analysis.
– 42% welcome GenAI as a post-appointment resource or medication information tool.
“As the healthcare community begins implementing GenAI applications, they must first understand and address the concerns Americans have about it being used in their care,” said Greg Samios, President and CEO of Clinical Effectiveness, Wolters Kluwer Health. “It will take responsible testing as well as understanding the importance of using the most current, highly vetted content developed by real medical experts to build acceptance of this new technology in clinical settings.”
Keep it Short
By KIM BELLARD OK, I admit it: I’m on Facebook. I still use Twitter – whoops, I mean X. I have an Instagram account but don’t think I’ve ever posted….
Asian Fund for Cancer Research announces Degron Therapeutics as the 2023 BRACE Award Venture Competition Winner
The Asian Fund for Cancer Research (AFCR) is pleased to announce that Degron Therapeutics was selected as the winner of the 2023 BRACE Award Venture Competition….
Seattle startup Olamedi building platform to automate health clinic communications
A new Seattle startup led by co-founders with experience in health tech is aiming to automate communication processes for healthcare clinics with its software…
